Navigation Links
Micromet, Inc. Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/13/2008

th chronic

lymphocytic leukemia is expected to be started in the United States by

Micromet's collaboration partner MedImmune. In addition, at the

conference of the American Society of Hematology (ASH) in December 2008,

Micromet anticipates that it will provide an update on the clinical

data of the ongoing clinical trials with MT103.

-- Micromet expects to initiate dosing of patients in a phase 1 clinical

trial of MT110 in patients with solid tumors in the first half of 2008.

-- Micromet is currently developing the study design for a clinical trial

to evaluate adecatumumab (MT201) in an adjuvant setting and plans to

initiate this clinical trial in the second half of 2008. In addition,

data of the ongoing phase 1b combination trial with docetaxel are

expected to be presented in the second half of 2008.

-- Micromet expects to initiate IND-enabling studies with MT203 as part of

its collaboration with Nycomed.

Conference Call and Audio Webcast Today, March 13, 2007, at 9:00am Eastern Time

To participate in this conference call, dial 800-561-2813 (U.S.) or 617-614-3529 (international), passcode: 29595857. The audio webcast can be accessed at: http://www.micromet-inc.com in the investor relations section of the website.

A replay of the call will be available from 11:00 am Eastern Time on March 13, 2008 (4:00 pm Central European Time) through Thursday, March 20, 2008. The replay number is 888-286-8010 (U.S.) or 617-801-6888 (international), passcode: 40638317.

About Micromet, Inc. (http://www.micromet-inc.com)

Micromet, Inc. is a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. Three of its antibodies are currently in clinical t
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Micromet, Inc. to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results
2. Micromet, Inc. Elects Joseph P. Slattery to Board of Directors
3. Micromet, Inc. to Present at the Sal. Oppenheim 2nd European Healthcare Conference
4. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
5. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
6. Helix BioPharma reports Q2 2008 highlights, financial results
7. Oncothyreon reports full year and fourth quarter 2007 financial results
8. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
9. Alfacell Reports Financial Results for Second Quarter of Fiscal 2008
10. ISTA Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
11. Oncolytics Biotech Inc. Reports Highlights and Financial Results for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... England , January 15, 2014 A ... win races on the Formula 1 track could help to ... McLaren Applied Technologies (MAT), Stowhealth (a GP surgery based in ... by healthcare provider Simplyhealth. Telemetry technology, which is ...
(Date:1/15/2014)... Reston, VA (PRWEB) January 15, 2014 ... education have continued their sponsorship of an annual competition ... interest in, and access to, innovative STEM study. The ... , TEAMS: Tests of Engineering Aptitude, Mathematics, and ...
(Date:1/15/2014)... 15, 2014 DTS Language Services, Inc ... Web Portal for Life Science organizations who need document translations. ... subject matter of their documents in advance with a selection ... time-to-delivery of translations, often a critical factor in clinical and ...
(Date:1/15/2014)... Freeslate, Inc ., the leading provider of ... one of India’s top five pharmaceutical companies, has received ... for high throughput solid form screening. , Lupin, ... range of quality, affordable generic and branded formulations and ...
Breaking Biology Technology:Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 2Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 3Formula 1 Technology Tackles Obesity in Unique Healthcare Partnership 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5DTS Improves Efficiency for Life Science Document Translations 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3
... All amounts are in U.S. dollars , , ... 13 /PRNewswire-FirstCall/ - Aeterna Zentaris Inc. ( AEZS, TSX: AEZ) ("the Company"), a late-stage ... at and for the three months ended March 31, 2010 . , ... First Quarter 2010 Highlights , , - January 25, 2010: ...
... BIRMINGHAM, Ala. , May 12 Atherotech Inc. will ... Association (NLA) Scientific Sessions 2010. The meeting takes place May 13-16 ... , , ... only advanced lipid test that routinely reports directly measured LDL-C, which is ...
... /PRNewswire-Asia-FirstCall/ -- NeoStem, Inc. (NYSE Amex:, NBS ) ("NeoStem" or the "Company"), an international biopharmaceutical ... at the NASDAQ MarketSite in Times Square, New York City . , ... NeoStem,s CEO, Dr. Robin Smith will provide ... , , ...
Cached Biology Technology:Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 2Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 3Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 4Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 5Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 6Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 7Aeterna Zentaris Reports First Quarter 2010 Financial and Operating Results 8Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 2Atherotech Emphasizes Predictive Value of VAP(R) Cholesterol Test at National Lipid Association Meeting 3NeoStem, Inc. to Present at NASDAQ MarketSite 2NeoStem, Inc. to Present at NASDAQ MarketSite 3
(Date:4/22/2014)... 22, 2014) Biotechnology scientists must be aware of ... and licensing guidelines, according to a new paper from ... in the current issue of the journal Regenerative ... 2013 U.S. Supreme Court ruling in the case Association ... occurring genes are unpatentable. The court case and rulings ...
(Date:4/22/2014)... PETA International Science Consortium Ltd.,s nanotechnology expert will present ... nanomaterial hazard assessment" at the 7th International Nanotoxicology ... Antalya, Turkey. , Dr. Monita Sharma will outline ... US National Academy of Sciences, " Toxicity Testing in ... which recommends use of non-animal methods involving human cells ...
(Date:4/22/2014)... Beaumont Health System with prestigious, competitive research grants ... and nonathletic injuries. , The American Orthopaedic ... to fund stem cell-based research that could help ... knee anterior cruciate ligament, or ACL. According to ... ligament injury is the over-stretching or tearing of ...
Breaking Biology News(10 mins):New patenting guidelines are needed for biotechnology 2New patenting guidelines are needed for biotechnology 3Beaumont awarded grants to study sports-related injury treatment, improve recovery 2
... RNA component units called ribonucleotides become embedded in genomic ... organism, they can cause problems for cells. It is ... DNA double helix, resulting in genomic instability and altered ... fate of these ribonucleotides. A new study provides ...
... UCLA life scientists and colleagues have produced the ... health of populations exposed to environmental change. ... Foundation, is published Dec. 2 in the journal ... projection model, or IPM, unites various sub-disciplines of population ...
... Most of us would agree that prevention is better than ... Rehabilitation , published by SAGE, indicate that a costly intervention ... Finland had no measurable effect. , The research was a ... participants and their 2440 matched controls for up to nine ...
Cached Biology News:Study identifies mechanisms cells use to remove bits of RNA from DNA strands 2Powerful mathematical model greatly improves predictions for species facing climate change 2Powerful mathematical model greatly improves predictions for species facing climate change 3Costly intervention program has no measurable effect on early retirement 2Costly intervention program has no measurable effect on early retirement 3
Animal Origin Free...
IHC Detection Kit (Broad Spectrum AEC)....
...
... Modification Services ,,GenScript offers many ... and antibody fragmentation. Labeling antibodies with ... visualization and quantitation of the target ... preferable to use only the antigen-binding ...
Biology Products: